FDA Panel to Review Peptide Drugs Amid Safety and Evidence Concerns
7 verified4 unconfirmed
The Food and Drug Administration is set to meet next month to reconsider the regulatory status of several injectable peptide therapies that have become popular among wellness influencers and supporters of Health Secretary Robert F. Kennedy Jr. FDA scientists posted documents Monday outlining concerns about the lack of rigorous clinical trial evidence for a batch of seven peptides, including BPC-157 and TB-500. The panel convening in July will largely be composed of doctors, pharmacists and other experts who have financial ties to the peptide industry, a shift from previous panels that were dominated by academic researchers. Secretary Kennedy has publicly stated he is a fan of peptides and has used them himself, and he has pushed for the agency to loosen restrictions that prevent compounding pharmacies from offering the drugs. The substances are typically marketed online and by wellness clinics as treatments for injuries, muscle recovery and anti-aging, though they have not been extensively studied in humans and are not FDA-approved. The two-day meeting is scheduled for July 23 and 24 and will review evidence for specific indications such as wound healing, obesity and migraines.
What’s verified
The FDA posted meeting materials on Monday, June 29 or 30, 2026, for a July panel on peptides.
The panel will consider seven peptides, including BPC-157 and TB-500.
FDA scientists have flagged a lack of sufficient evidence and potential safety concerns for these peptides.
Health Secretary Robert F. Kennedy Jr. has expressed support for peptides and said he has used them.
The panel members include individuals with industry ties, such as doctors and pharmacists who prescribe, produce or promote peptides.
The meeting is expected to last two days, on July 23 and 24.
Many of these peptides are obtained through compounding pharmacies or a gray market, and they are often labeled "for research use only."
Not yet confirmed
The exact number of panelists with industry ties was not consistently reported across sources; one source noted "more than a half-dozen," while the other did not specify a count.
Whether the panel will ultimately recommend changing the designation for any of the seven peptides remains uncertain.
It is unclear how the panel will weigh the FDA scientists' concerns against the industry-connected members' views.
A previous FDA panel on compounding voted against similar peptide ingredients; whether the current panel's composition will lead to a different outcome is not known.
Key figures
Robert F. Kennedy Jr. – Health Secretary
Dr. Alexander Weber – orthopedic surgeon, University of Southern California
Dr. Haleem Mohammed – panelist, runs clinics in Florida
Dr. Gabriel Alizaidy – panelist, peptide consultant
Bobby Harshbarger – Tennessee state senator, panelist
Rep. Diana Harshbarger – U.S. Congress member from Tennessee
Marty Makary – former FDA Commissioner
President Donald Trump – former president
Sources: NPR, abcnews.com
